Darolutamide Plus ADT in Metastatic Hormone-Sensitive Prostate Cancer

(MedPage Today) — New data presented at the American Urological Association (AUA) annual meeting further supported the use of darolutamide (Nubeqa) in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive…

Source link : https://www.medpagetoday.com/meetingcoverage/auavideopearls/115825

Author :

Publish date : 2025-05-30 17:50:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30

Darolutamide Plus ADT in Metastatic Hormone-Sensitive Prostate Cancer

CDC Now Advises Shared Decision-Making for Kids’ COVID Shots

COVID Vaccine Guidance in Pregnancy Has Shifted — But the Science Hasn’t

Related Posts

VA Restricts Research Publishing; Makary Bashes CDC Committee; Musk’s Drug Use

Novel Algorithm Boosts Stroke Triage, Outcomes Across the US

Trillion dollars’ worth of platinum waiting to be mined on the moon

EoE Prevalence in US Reaches 1 in 700, Costs $1B Annually

ADC-Pertuzumab Promising as New Standard in HER2-Positive Metastatic Breast Cancer

Measles Update: Where Are We Now?

VA Restricts Research Publishing; Makary Bashes CDC Committee; Musk’s Drug Use

Novel Algorithm Boosts Stroke Triage, Outcomes Across the US

Trillion dollars’ worth of platinum waiting to be mined on the moon

EoE Prevalence in US Reaches 1 in 700, Costs $1B Annually

ADC-Pertuzumab Promising as New Standard in HER2-Positive Metastatic Breast Cancer

Measles Update: Where Are We Now?

Manslaughter case launched into Nottingham baby deaths

Dogs pollute water with pesticides even weeks after flea treatment

Categories

Archives